Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma
Jennifer L. Tomlinson,Binbin Li,Jingchun Yang,Emilien Loeuillard,Hannah E. Stumpf,Hendrien Kuipers,Ryan Watkins,Danielle M. Carlson,Jessica Willhite,Daniel R. O’Brien,Rondell P. Graham,Xin Chen,Rory L. Smoot,Haidong Dong,Gregory J. Gores,Sumera I. Ilyas
DOI: https://doi.org/10.1016/j.jhep.2024.02.008
IF: 25.7
2024-03-09
Journal of Hepatology
Abstract:Background & Aims Cholangiocarcinoma (CCA) is a poorly immunogenic malignancy with limited survival. Syngeneic, immunocompetent mouse models of CCA are an essential tool to elucidate the tumor immune microenvironment (TIME), understand mechanisms of tumor immune evasion, and test novel immunotherapeutic strategies. The scope of this study was to develop and characterize immunocompetent CCA models with distinct genetic drivers, and correlate tumor genomics, immunobiology, and therapeutic response. Methods A multifaceted approach including scRNA-seq, CITE-seq, whole exome and RNA sequencing was employed. FDA-approved PD-1/PD-L1 antibodies were tested in humanized PD-1/PD-L1 mice (HuPD-H1). Results A genetic mouse model of intrahepatic CCA (iCCA) driven by intrabiliary transduction of Fbxw7ΔF/ Akt that mimics human iCCA was generated. From the Fbxw7ΔF/ Akt tumors, a murine cell line (FAC) and syngeneic model with genetic and phenotypic characteristics of human iCCA were developed. Established SB1 ( YAP / Akt ) and KPPC ( Kras G12D p53 L/L ) models were compared to the FAC model. Although the models had transcriptomic similarities, they had substantial differences as well. Mutation patterns of SB1, KPPC, and FAC cells matched different mutation signatures in Western and Japanese CCA patient cohorts. KPPC tumors had a high tumor mutation burden. FAC tumors had a T cell-infiltrated TIME, while SB1 tumors had a preponderance of suppressive myeloid cells. SB1, FAC, and KPPC tumors matched different immune signatures in human iCCA cohorts. Moreover, SB1, KPPC, and FAC tumor-bearing HuPD-H1 mice had differential responses to nivolumab or durvalumab. Conclusions Syngeneic iCCA models display a tumor genotype-immune microenvironment phenotype correlation with differential responses to FDA-approved immunotherapy. This study underscores the importance of leveraging multiple preclinical models to understand immunotherapy response in different genetic subsets of human CCA.
gastroenterology & hepatology